APA (7th ed.) Citation

H, N., T, S., T, K., K, I., & D, T. (2026). NFE2L2 rs35652124C>T polymorphism predicts Grade 4 neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and fluorouracil chemotherapy: Results from exploratory and validation cohorts. Cancer chemotherapy and pharmacology, 96(1), . https://doi.org/10.1007/s00280-026-04866-0

Chicago Style (17th ed.) Citation

H, Nomura, Suzuki T, Kojima T, Itoh K, and Tsuji D. "NFE2L2 Rs35652124C>T Polymorphism Predicts Grade 4 Neutropenia in Esophageal Cancer Patients Treated with Docetaxel, Cisplatin, and Fluorouracil Chemotherapy: Results from Exploratory and Validation Cohorts." Cancer Chemotherapy and Pharmacology 96, no. 1 (2026). https://doi.org/10.1007/s00280-026-04866-0.

MLA (9th ed.) Citation

H, Nomura, et al. "NFE2L2 Rs35652124C>T Polymorphism Predicts Grade 4 Neutropenia in Esophageal Cancer Patients Treated with Docetaxel, Cisplatin, and Fluorouracil Chemotherapy: Results from Exploratory and Validation Cohorts." Cancer Chemotherapy and Pharmacology, vol. 96, no. 1, 2026, https://doi.org/10.1007/s00280-026-04866-0.